Pegaspargase

證據等級: L5

預測適應症: 10 個

Pegaspargase: From Acute Lymphoblastic Leukemia to Precursor Lymphoblastic Lymphoma/Leukemia

One-Sentence Summary

Pegaspargase (PEG-L-asparaginase, DrugBank DB00059) is an enzyme-based antineoplastic agent with an established, FDA-approved role in acute lymphoblastic leukemia (marketed as Oncaspar). The TxGNN model’s top-ranked prediction — Precursor Lymphoblastic Lymphoma/Leukemia — is the same biological disease entity as its known indication, supported by 53 clinical trials and 20 publications, functioning here primarily as a benchmark validation of the model rather than a novel repurposing signal.

Quick Overview

Item	Content
Original Indication	Acute Lymphoblastic Leukemia (established/approved use, referenced as Oncaspar in evidence base; no formal license record in this dataset)
Predicted New Indication	Precursor lymphoblastic lymphoma/leukemia
TxGNN Prediction Score	99.96%
Evidence Level	L1
Market Status	Not Marketed (0 licenses on file)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, a formal DrugBank-sourced mechanism of action record is not available in this evidence pack (flagged as a High-severity data gap, DG002). However, the model’s own rationale field supplies sufficient mechanistic detail: pegaspargase depletes circulating asparagine. Precursor lymphoblastic (B- or T-cell) leukemia/lymphoma cells characteristically lack sufficient asparagine synthetase activity to synthesize their own asparagine, so systemic depletion selectively starves and induces apoptosis in these blasts while sparing most normal tissues, which can synthesize their own supply.

Critically, “precursor lymphoblastic lymphoma/leukemia” is not a distinct new disease relative to pegaspargase’s original use — it is essentially the same biological entity as classic acute lymphoblastic leukemia (ALL), which is pegaspargase’s core, decades-old, guideline-standard indication (as reflected in the model’s own annotation for the related candidate “acute lymphoblastic leukemia,” rank 5, which explicitly cites this as the approved Oncaspar indication). This candidate therefore functions less as a discovery of a new use and more as internal validation that the TxGNN knowledge graph correctly recovers a drug’s known, ground-truth indication — a useful sanity check on model calibration, but not itself a repurposing opportunity requiring new clinical development.

Supporting mechanistic literature (e.g., Fu & Sakamoto, Expert Opin Pharmacother 2007, PMID 17696798) confirms that L-asparaginase efficacy across nearly 40 years of leukemia therapy is attributable to this asparagine-depletion mechanism, reinforcing the biological plausibility of the prediction even though a structured MOA field is missing from the drug record.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02716233	Phase 3	Active, not recruiting	2,044	French national protocol for pediatric/adolescent ALL investigating optimal L-asparaginase use across treatment phases
NCT03020030	Phase 3	Active, not recruiting	560	Large-scale treatment protocol for newly diagnosed ALL in children/adolescents with pegaspargase as an induction component
NCT00003437	Phase 3	Unknown	1,800	UK national trial (MRC) comparing steroid/chemotherapy regimens including asparaginase-based induction in childhood ALL
NCT04954326	Phase 2	Completed	89	Pharmacokinetic comparison of liquid vs lyophilized pegaspargase formulations during induction in newly diagnosed pediatric ALL
NCT06195735	N/A	Completed	649	Predictive modeling of PEG-asparaginase hypersensitivity to optimize outcomes across NOPHO/ALLTogether protocols
NCT00905034	Phase 2	Completed	37	MOAD regimen (methotrexate, vincristine, pegylated L-asparaginase, dexamethasone) for relapsed/refractory ALL salvage
NCT00187083	Phase 3	Completed	40	Head-to-head comparison of native vs PEG-asparaginase during induction for relapsed/refractory pediatric ALL
NCT02881086	Phase 3	Completed	1,023	Individualized, MRD-directed adult ALL/lymphoblastic lymphoma treatment optimization incorporating asparaginase intensification
NCT00198991	Phase 4	Completed	1,883	GMALL 07/2003 German multicenter adult/adolescent ALL trial with risk-stratified consolidation and MRD monitoring
NCT00882206	Phase 2	Terminated	15	Decitabine/vorinostat plus VPLD chemotherapy (including PEG-asparaginase) for relapsed/refractory ALL/lymphoblastic lymphoma

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35271306	2022	RCT	J Clin Oncol	COG AALL1231 phase 3 trial testing bortezomib in newly diagnosed T-ALL/T-LL, within a standard asparaginase-containing backbone
27114587	2016	RCT	J Clin Oncol	COG AALL0232: dexamethasone and high-dose methotrexate improve outcomes in high-risk B-ALL
32813610	2020	RCT	J Clin Oncol	COG AALL0434 phase 3 trial of nelarabine in newly diagnosed T-ALL
34228505	2021	Cohort	J Clin Oncol	DFCI 11-001: efficacy/toxicity comparison of pegaspargase vs calaspargase pegol in childhood ALL
37276451	2023	Cohort	Blood Adv	GIMEMA LAL1913: pegaspargase-modified risk-oriented program for adult ALL
31571395	2020	Cohort	Pediatr Blood Cancer	Rapid desensitization protocol allowing continued pegaspargase use in hypersensitive pediatric patients
40109190	2025	Review	Haematologica	Expert panel consensus on recognition, prevention, and management of asparaginase/pegaspargase adverse events in adults
17696798	2007	Review	Expert Opin Pharmacother	Foundational review of PEG-asparaginase pharmacology, mechanism, and clinical role in leukemia
40163215	2025	Phase 2	Int J Hematol	Multicenter Japanese phase 2 study of pegaspargase efficacy, safety, and PK in previously untreated ALL
36227415	2022	Cost-Utility	Clin Drug Investig	Cost-utility analysis of pegaspargase vs L-asparaginase sequencing in Greek ALL patients

US Market Information

Currently no license/authorization records are on file for this drug in the evaluated jurisdiction (0 licenses; market status: Not Marketed). Pegaspargase is independently known to be marketed elsewhere as Oncaspar for ALL, but no local regulatory data confirms this within the current evidence pack.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — enzyme-based antineoplastic (L-asparagine depletion; ATC L01XX02)
Myelosuppression Risk	Low as a single agent (asparaginase itself is not strongly myelosuppressive); however it is typically given within multi-agent regimens (e.g., with vincristine, anthracyclines, corticosteroids) where cumulative marrow suppression risk is significant
Emetogenicity Classification	Low to moderate
Monitoring Items	Hepatic function (risk of hepatotoxicity), pancreatic enzymes/lipase (risk of pancreatitis), coagulation panel (fibrinogen, antithrombin — thrombosis/bleeding risk), triglycerides and glucose (hypertriglyceridemia, hyperglycemia), and serum asparaginase activity where available; close monitoring for hypersensitivity/anaphylaxis during and after infusion
Handling Protection	Must follow standard cytotoxic/hazardous antineoplastic drug handling regulations

Safety Considerations

Please refer to the package insert for safety information. No structured warnings, contraindications, or drug-drug interaction data were available in this evidence pack (TFDA/local label data flagged as a Blocking data gap, DG001).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Evidence level L1 (multiple completed/active Phase 3 trials plus RCTs) strongly supports pegaspargase’s role in precursor lymphoblastic leukemia/lymphoma — but this is confirmatory of its already-known indication rather than a genuine new-use discovery, and two Blocking/High-severity data gaps (local safety labeling, formal MOA) currently prevent a full S1 safety review.

To proceed, the following is needed:

Local package insert / TFDA-equivalent warnings, contraindications, and DDI data (DG001, Blocking)
Formal DrugBank-sourced mechanism-of-action record (DG002, High)
Clarification of actual market/licensing status, since 0 licenses are currently on file despite known global marketing as Oncaspar
Given rank-1 is essentially a validation case, prioritize independent review of higher-uncertainty candidates in this pack (e.g., “lymphoid neoplasm” and the trial set mislabeled as “Hodgkin lymphoma,” which is largely evidence for extranodal NK/T-cell lymphoma — a disease-ontology mapping check is recommended before further action on that candidate)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.